Amicus shares surge on preclinical Pompe disease results; Isis earns $5M payment from Biogen Idec;

@FierceBiotech: $MRK and $NVO join an open-source R&D club with $AMGN, $SNY and Ono. Report | Follow @FierceBiotech

@JohnCFierce: Game-changer: A new plan takes shape to spur the U.K.'s biotech cluster. More | Follow @JohnCFierce

@DamianFierce: Schleifer on PCSK9 launches: Initial splash w/ severe patients and "early adopters" followed by a 2nd boom when outcomes data come out $REGN. | Follow @DamianFierce

> Shares of Amicus Therapeutics surged this morning after the biotech released some preclinical results on its therapy for Pompe disease. Release

> Isis ($ISIS) earned a $5 million milestone from Biogen Idec ($BIIB) in exchange for progress on an unidentified neurological disorder. Release

Medical Device News

@FierceMedDev: Biosensors Japan's PhIII trial of drug eluting has enrolled patients. More | Follow @FierceMedDev

@VarunSaxena2: Check out these next-gen devices in the incubator pipeline: (Lots of pictures of new devices.) Report | Follow @VarunSaxena2

@EmilyWFierce: Pioneer in BRCA1 research once received a cease-and-desist letter from $MYGN's legal department. NYT story | Follow @EmilyWFierce

> Ahead of BD deal close, CareFusion partners to sell ventilators, sleep apnea device. Story

> Days after permanent injunction, Maquet is whacked with another FDA recall. Article

Pharma News

@FiercePharma: ICYMI yesterday: Serum Institute and Cipla in early merger talks. Story from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Daiichi's new clot-fighter Savaysa can't make up for $2.6B Benicar patent loss: analysts. Article | Follow @CarlyHFierce

> FDA puts off Mylan's Nexium generic, giving Teva's version free rein. More

> Showdown time for Amgen, Sandoz, with Neupogen biosim hearing set March 2. Article

Pharma Manufacturing News

> Cambrex ponies up $50M for another expansion of its Iowa API plant. News

> New Jersey company invests $1M in plant, now offers contract manufacturing. Article

> FDA letter takes issue with Micro Labs' data practices. Report

> China FDA orders respiratory API recalled after 'fur' like impurities found. Story

> Cipla to build a manufacturing plant in Morocco with local partners. Article

Biotech Research News

> UC Davis team finds a prime drug candidate for neuropathic pain. More

> Neuroscience project tries to put the immune system to work against Alzheimer's. Report

> Psychedelic drug shows promise as a new treatment for allergic asthma. Article

> Peptide could play a role in preventing binge eating, obesity. Item

> Antibody developed by NTU-led team in Singapore tracks flu recovery. Story

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.